Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 7,980 Shares

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total transaction of $136,857.00. Following the sale, the chief financial officer owned 17,338 shares of the company’s stock, valued at $297,346.70. The trade was a 31.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Wednesday, April 1st, Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.77, for a total value of $133,807.83.

Avalo Therapeutics Price Performance

AVTX remained flat at $17.76 on Friday. The company’s stock had a trading volume of 1,109,141 shares, compared to its average volume of 845,897. The firm’s fifty day moving average is $15.50 and its 200-day moving average is $15.91. The stock has a market capitalization of $404.75 million, a price-to-earnings ratio of -3.10 and a beta of 0.93. Avalo Therapeutics, Inc. has a 12 month low of $3.39 and a 12 month high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of ($0.21) million. As a group, equities analysts anticipate that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current year.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AVTX. BIT Capital GmbH purchased a new position in Avalo Therapeutics during the third quarter worth approximately $25,000. PFS Partners LLC increased its position in shares of Avalo Therapeutics by 100.0% in the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after buying an additional 1,000 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Avalo Therapeutics during the 2nd quarter worth approximately $55,000. Boothbay Fund Management LLC acquired a new position in shares of Avalo Therapeutics during the 2nd quarter worth approximately $56,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Avalo Therapeutics during the 3rd quarter valued at approximately $143,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on AVTX shares. HC Wainwright boosted their target price on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a report on Tuesday, March 24th. Guggenheim started coverage on Avalo Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price target for the company. Finally, Wall Street Zen upgraded Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Avalo Therapeutics has an average rating of “Moderate Buy” and an average target price of $42.25.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.